File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Bradykinin-induced contractions of canine saphenous veins: Mediation by B2 receptors and involvement of eicosanoids

TitleBradykinin-induced contractions of canine saphenous veins: Mediation by B2 receptors and involvement of eicosanoids
Authors
KeywordsBradykinin
Bradykinin receptor
Canine saphenous vein
Cyclo-oxygenase
Lipoxygenase
Issue Date1997
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1
Citation
British Journal Of Pharmacology, 1997, v. 120 n. 2, p. 215-220 How to Cite?
Abstract1. Experiments were designed to determine the subtype of kinin-receptors mediating the contraction of venous smooth muscle to bradykinin and to investigate the involvement of metabolites of arachidonic acid in this response. 2. Bradykinin (10-9 to 10-6 M) caused concentration-dependent contractions of the canine isolated saphenous vein without endothelium, which were potentiated by indomethacin (10-5 M, an inhibitor of cyclo-oxygenase). The concentration-response curve was biphasic, reaching an asymptote at 10-8 M and a secondary maximal response at 10-6 M. 3. Bradykinin (10-8 M to 3 x 10-6 M) caused a three fold stimulation in the release of the vasodilator prostaglandin E2 (PGE2) and a two fold stimulation of that of the vasodilator prostacyclin, measured by the production of 6-keto-PGF(1α) (its stable breakdown product). 4. Under control conditions, nordihydroguaiaretic acid (NDGA, 10-5 M), an inhibitor of lipoxygenase, did not affect the response to bradykinin. In the presence of indomethacin (10-5 M), NDGA reduced contractions to bradykinin, suggesting the involvement of lipoxygenase metabolites in the potentiation evoked by the inhibitor of cyclo-oxygenase. 5. The selective B1 receptor agonist [des-Arg9]-bradykinin, in the concentration-range 10-6 to 10-5 M, induced contractions, which were abolished by the B2 receptor antagonist D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin (Hoe 140, 10-6 M). The selective B1 receptor antagonist [des-Arg9,Leu8]-bradykinin, (10-7 to 10-5 M) had no significant effect on bradykinin-induced contractions. 6. The B2 receptor antagonists Hoe 140 (10-8 to 10-6 M) and D-Arg[Hyp3,D-Phe7]-bradykinin (10-7 to 10-5 M) shifted the concentration-response curve to bradykinin to the right in a concentration-dependent manner. 7. These results indicate that, in the canine saphenous vein, bradykinin causes contraction by activating B2 receptors. This results in the production of metabolites of arachidonic acid, which play a key role in the contraction of canine saphenous venous smooth muscle.
Persistent Identifierhttp://hdl.handle.net/10722/171202
ISSN
2023 Impact Factor: 6.8
2023 SCImago Journal Rankings: 2.119
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMarsault, Ren_US
dc.contributor.authorIlliano, Sen_US
dc.contributor.authorVanhoutte, PMen_US
dc.date.accessioned2012-10-30T06:12:40Z-
dc.date.available2012-10-30T06:12:40Z-
dc.date.issued1997en_US
dc.identifier.citationBritish Journal Of Pharmacology, 1997, v. 120 n. 2, p. 215-220en_US
dc.identifier.issn0007-1188en_US
dc.identifier.urihttp://hdl.handle.net/10722/171202-
dc.description.abstract1. Experiments were designed to determine the subtype of kinin-receptors mediating the contraction of venous smooth muscle to bradykinin and to investigate the involvement of metabolites of arachidonic acid in this response. 2. Bradykinin (10-9 to 10-6 M) caused concentration-dependent contractions of the canine isolated saphenous vein without endothelium, which were potentiated by indomethacin (10-5 M, an inhibitor of cyclo-oxygenase). The concentration-response curve was biphasic, reaching an asymptote at 10-8 M and a secondary maximal response at 10-6 M. 3. Bradykinin (10-8 M to 3 x 10-6 M) caused a three fold stimulation in the release of the vasodilator prostaglandin E2 (PGE2) and a two fold stimulation of that of the vasodilator prostacyclin, measured by the production of 6-keto-PGF(1α) (its stable breakdown product). 4. Under control conditions, nordihydroguaiaretic acid (NDGA, 10-5 M), an inhibitor of lipoxygenase, did not affect the response to bradykinin. In the presence of indomethacin (10-5 M), NDGA reduced contractions to bradykinin, suggesting the involvement of lipoxygenase metabolites in the potentiation evoked by the inhibitor of cyclo-oxygenase. 5. The selective B1 receptor agonist [des-Arg9]-bradykinin, in the concentration-range 10-6 to 10-5 M, induced contractions, which were abolished by the B2 receptor antagonist D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin (Hoe 140, 10-6 M). The selective B1 receptor antagonist [des-Arg9,Leu8]-bradykinin, (10-7 to 10-5 M) had no significant effect on bradykinin-induced contractions. 6. The B2 receptor antagonists Hoe 140 (10-8 to 10-6 M) and D-Arg[Hyp3,D-Phe7]-bradykinin (10-7 to 10-5 M) shifted the concentration-response curve to bradykinin to the right in a concentration-dependent manner. 7. These results indicate that, in the canine saphenous vein, bradykinin causes contraction by activating B2 receptors. This results in the production of metabolites of arachidonic acid, which play a key role in the contraction of canine saphenous venous smooth muscle.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1en_US
dc.relation.ispartofBritish Journal of Pharmacologyen_US
dc.subjectBradykinin-
dc.subjectBradykinin receptor-
dc.subjectCanine saphenous vein-
dc.subjectCyclo-oxygenase-
dc.subjectLipoxygenase-
dc.subject.meshAnimalsen_US
dc.subject.meshBradykinin - Pharmacologyen_US
dc.subject.meshDogsen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshEicosanoids - Physiologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshIndomethacin - Pharmacologyen_US
dc.subject.meshMaleen_US
dc.subject.meshNordihydroguaiaretic Acid - Pharmacologyen_US
dc.subject.meshReceptor, Bradykinin B2en_US
dc.subject.meshReceptors, Bradykinin - Physiologyen_US
dc.subject.meshSaphenous Vein - Drug Effects - Physiologyen_US
dc.subject.meshVasoconstriction - Drug Effectsen_US
dc.titleBradykinin-induced contractions of canine saphenous veins: Mediation by B2 receptors and involvement of eicosanoidsen_US
dc.typeArticleen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/sj.bjp.0700898en_US
dc.identifier.pmid9117112-
dc.identifier.scopuseid_2-s2.0-0031036732en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0031036732&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume120en_US
dc.identifier.issue2en_US
dc.identifier.spage215en_US
dc.identifier.epage220en_US
dc.identifier.isiWOS:A1997WC77800007-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridMarsault, R=6603857574en_US
dc.identifier.scopusauthoridIlliano, S=6602119848en_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US
dc.identifier.issnl0007-1188-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats